

October 25, 2024

Tο

Listing Department,

NATIONAL STOCK EXCHANGE OF INDIA LIMITED

Exchange Plaza,

Bandra Kurla Complex, Bandra (E),

MUMBAI -400 051

Company Code No. AUROPHARMA

To

The Corporate Relations Department

BSE LIMITED

Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street,

MUMBAI -400 001

Company Code No. 524804

Dear Sir/ Madam,

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Completion of acquisition of balance 49% of equity shares of GLS Pharma Limited.

Ref: Our letter dated September 18, 2024.

We refer our earlier letter dated September 18, 2024, informing that the Company entered into a binding agreement on September 18, 2024, with GLS Pharma Limited (GLS), a subsidiary of the Company and its promoters, for acquisition of balance 5,90,361 equity shares of INR 10/- each (49% of GLS) for a purchase consideration of INR 22.5 crores.

In this regard, we wish to update you that the aforementioned acquisition has been completed on October 25, 2024 and GLS has become a wholly owned subsidiary of the Company.

This submission is being made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Please take the above information on record.

Thanking you,

Yours faithfully,
For AUROBINDO PHARMA LIMITED

B. Adi Reddy Company Secretary

(CIN: L24239TG1986PLC015190)

AUROBINDO PHARMA LIMITED

www.aurobindo.com

PAN No. AABCA7366H

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.

Tel: +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.